In 2021, Gongdong Medical achieved operating income of CNY 1.194 billion, a year-on-year increase of 43.95%; net profit attributable to the parent company of CNY 311 million, a year-on-year increase of 37.68%.

Thermo Fisher Scientific has launched its first GMP-manufactured Cas9 protein for clinical genome editing research.

Chinese diagnostics firm Amoy Diagnostics on Monday announced that it has entered into a collaboration agreement with AstraZeneca to develop and commercialize AmoyDx assays that may cover any type of indication or biomarker for companion diagnostic use with AstraZeneca medicines.

On April 15, Wuhan Easy Diagnosis Biomedicine, Shenzhen YHLO Biotech and Acrobiosystemsreleased its first quarter results forecast for 2022

Eurobio Scientific said on Thursday that its molecular SARS-CoV-2 test for detecting viral variants has received CE marking.

The US Food and Drug Administration this week granted Emergency Use Authorization for the Cleveland Clinic's SelfCheck Cobas SARS-CoV-2 + Flu Assay.

Shanghai Rigen Biotech Co., Ltd. (hereinafter referred to as "Rigen") recently completed a new round of financing of nearly 100 million CNY.

The US Food and Drug Administration on Thursday announced it has granted Emergency Use Authorization to InspectIR Systems' InspectIR COVID-19 Breathalyzer test, making it the first breath-based test for detecting SARS-CoV-2 to receive such designation.

Shanghai Fosun Pharmaceutical on Thursday announced that China's National Medical Products Administration (NMPA) has granted approval for Fosun Diagnostic's Novel Coronavirus (2019-nCoV) Antigen Detection Kit (Colloidal Gold) for COVID-19 screening.

On April 13, the SARS-CoV-2 Rapid Antigen Test (immunochromatography Assay) developed by Sansure Biotech Inc. has obtained CE certification! This means that the test can be sold in EU countries and countries that recognize EU CE certification.

C2i Genomics launches minimal residual disease test across Europe after clearing regulatory hurdles in the EU, UK, and Switzerland.

BioMérieux on Tuesday announced it has entered into an agreement to acquire Specific Diagnostics for an acquisition price equivalent to 3.3 percent of BioMérieux's market capitalization as of April 11, paid with a combination of cash and shares issued to Specific Diagnostics shareholders.

On April 13, National Medical Products Administrations (NMPA) reviewed and approved Zhuhai Livzon Diagnostics Inc. and Shanghai BioGerm Medical Technology Co., Ltd's COVID-19 Antigen Test.

The US Food and Drug Administration last week granted separate Emergency Use Authorizations for a PCR-based SARS-CoV-2 test developed by the University of California, San Diego and an at-home nasal specimen collection kit from the Washington D.C. Department of Health.

Medical advances are causing a gradual increase in average life expectancy. However, this comes at a price, as the number of cases of dementia and other neurodegenerative diseases grows with age.